Alexion Overview
- Year Founded
-
1992

- Status
-
Acquired/Merged
- Employees
-
4,759

- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$41.1B
Alexion General Information
Description
Dveloper of biopharmaceutical drugs intended to transform the lives of people affected by rare diseases and devastating conditions. The company is involved in biotechnology research and offers therapies that treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) among others, enabling individuals to overcome the issues they face every day.
Contact Information
Website
www.alexion.com(Operating Subsidiary)
Corporate Office
- 121 Seaport Boulevard
- Boston, MA 02210
- United States
Corporate Office
- 121 Seaport Boulevard
- Boston, MA 02210
- United States
Alexion Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
10. Merger/Acquisition | 21-Jul-2021 | $41.1B | Completed | Profitable | ||
9. Merger/Acquisition | 06-Dec-2019 | Cancelled | Profitable | |||
8. Debt Refinancing | 30-Apr-2018 | Completed | Profitable | |||
7. PIPE | 10-Mar-2018 | Completed | Profitable | |||
6. PIPE | 06-Aug-2017 | Completed | Profitable | |||
5. Debt - Acquisition | 23-Jun-2015 | Completed | Profitable | |||
4. 2PO | 23-May-2012 | Completed | Profitable | |||
3. Debt - Acquisition | 31-Jan-2012 | Completed | Profitable | |||
2. IPO | 28-Feb-1996 | Completed | Profitable | |||
1. Early Stage VC | 01-Jan-1994 | Completed | Profitable |
Alexion Comparisons
Industry
Financing
Details
Alexion Competitors (41)
One of Alexion’s 41 competitors is NexImmune, a Formerly VC-backed company based in Gaithersburg, MD.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
TiGenix | Formerly VC-backed | Leuven, Belgium | ||||
Hansa Biopharma | Corporation | Lund, Sweden | ||||
Cristal Therapeutics | Venture Capital-Backed | Maastricht, Netherlands | ||||
Genentech | Formerly VC-backed | South San Francisco, CA |
Alexion Patents
Alexion Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2023352679-A1 | Dosage and administration of anti-c5 antibodies for preventing or minimizing cardiac surgery associated acute kidney injury (csa-aki) and/or subsequent major adverse kidney events (make) in patients with chronic kidney disease | Pending | 28-Sep-2022 | ||
AU-2023338677-A1 | Supplemental dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) | Pending | 06-Sep-2022 | ||
AU-2023280383-A1 | Dosage and administration of fusion polypeptides for treatment of myasthenia gravis | Pending | 03-Jun-2022 | ||
EP-4532533-A2 | Dosage and administration of fusion polypeptides for treatment of myasthenia gravis | Pending | 03-Jun-2022 | ||
EP-4522988-A1 | High sensitivity biotinylated peptide binding elisa assay | Pending | 11-May-2022 | C07K16/18 |
Alexion Signals
Alexion Former Investors (17)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Alkeon Capital Management | Venture Capital | Minority | ||
BB Biotech | Asset Manager | Minority | ||
BMO Financial Group | Corporation | Minority | ||
Bank of the West | Corporation | Minority | ||
CHL Medical Partners | Venture Capital | Minority |
Alexion Investments & Acquisitions (27)
Alexion’s most recent deal was a Corporate Asset Purchase with Pfizer (Early-Stage Gene Therapy Portfolio) for . The deal was made on 20-Sep-2023.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Pfizer (Early-Stage Gene Therapy Portfolio) | 20-Sep-2023 | Corporate Asset Purchase | Buildings and Property | ||
Verge Genomics | 08-Sep-2023 | Later Stage VC | Drug Discovery | ||
LogicBio Therapeutics | 16-Nov-2022 | Merger/Acquisition | Biotechnology | ||
Caelum Biosciences | 06-Oct-2021 | Merger/Acquisition | Biotechnology | ||
Rhythm Pharmaceuticals (Rare Pediatric Disease Priority Review Voucher in Boston, Massachusetts) | 01-Feb-2021 | Corporate Asset Purchase | Buildings and Property |
Alexion ESG
Risk Overview
Risk Rating
Updated March, 25, 2022
14.78 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,480
Rank
Percentile

Pharmaceuticals
Industry
of 905
Rank
Percentile

Biotechnology
Subindustry
of 404
Rank
Percentile

Alexion Affiliates
Subsidiaries (2)
Name | Industry | Location | Year Founded |
---|---|---|---|
Complement Pharma | Amsterdam, Netherlands | 2009 | |
Prothelia | Milford, MA | 2007 |
Alexion FAQs
-
When was Alexion founded?
Alexion was founded in 1992.
-
Where is Alexion headquartered?
Alexion is headquartered in Boston, MA.
-
What is the size of Alexion?
Alexion has 4,759 total employees.
-
What industry is Alexion in?
Alexion’s primary industry is Drug Discovery.
-
Is Alexion a private or public company?
Alexion is a Private company.
-
What is the current valuation of Alexion?
The current valuation of Alexion is
. -
What is Alexion’s current revenue?
The current revenue for Alexion is
. -
How much funding has Alexion raised over time?
Alexion has raised $3.61B.
-
Who are Alexion’s investors?
Alkeon Capital Management, BB Biotech, BMO Financial Group, Bank of the West, and CHL Medical Partners are 5 of 17 investors who have invested in Alexion.
-
Who are Alexion’s competitors?
NexImmune, TiGenix, Hansa Biopharma, Cristal Therapeutics, and Genentech are some of the 41 competitors of Alexion.
-
When was Alexion acquired?
Alexion was acquired on 21-Jul-2021.
-
Who acquired Alexion?
Alexion was acquired by AstraZeneca.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »